[1]
Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management., Gertz MA,, American journal of hematology, 2015 Apr [PubMed PMID: 25808108]
[2]
Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia., Naderi N,Yang DT,, Archives of pathology & laboratory medicine, 2013 Apr [PubMed PMID: 23544948]
[3]
Swerdlow SH,Campo E,Pileri SA,Harris NL,Stein H,Siebert R,Advani R,Ghielmini M,Salles GA,Zelenetz AD,Jaffe ES, The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May 19; [PubMed PMID: 26980727]
[4]
Biology, prognosis, and therapy of Waldenström Macroglobulinemia., Castillo JJ,Ghobrial IM,Treon SP,, Cancer treatment and research, 2015 [PubMed PMID: 25655610]
[5]
Yun S,Johnson AC,Okolo ON,Arnold SJ,McBride A,Zhang L,Baz RC,Anwer F, Waldenström Macroglobulinemia: Review of Pathogenesis and Management. Clinical lymphoma, myeloma [PubMed PMID: 28366781]
[6]
Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study., Castillo JJ,D'Sa S,Lunn MP,Minnema MC,Tedeschi A,Lansigan F,Palomba ML,Varettoni M,Garcia-Sanz R,Nayak L,Lee EQ,Rinne ML,Norden AD,Ghobrial IM,Treon SP,, British journal of haematology, 2015 Dec 21 [PubMed PMID: 26686858]
[7]
Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression., Cao X,Medeiros LJ,Xia Y,Wang X,Thomas SK,Loghavi S,Li X,Shah JJ,Gustafson SA,Weber DM,Miranda RN,Xu-Monette ZY,Orlowski RZ,Young KH,, Leukemia & lymphoma, 2015 Dec 23 [PubMed PMID: 26421453]
[8]
Castillo JJ,Treon SP, Initial Evaluation of the Patient with Waldenström Macroglobulinemia. Hematology/oncology clinics of North America. 2018 Oct; [PubMed PMID: 30190019]
[9]
Lymphoplasmacytic lymphoma and marginal zone lymphoma in the bone marrow: paratrabecular involvement as an important distinguishing feature., Bassarova A,Trøen G,Spetalen S,Micci F,Tierens A,Delabie J,, American journal of clinical pathology, 2015 Jun [PubMed PMID: 25972321]
[10]
Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database., Castillo JJ,Olszewski AJ,Hunter ZR,Kanan S,Meid K,Treon SP,, Cancer, 2015 Mar 10 [PubMed PMID: 25757851]
[11]
MYD88 mutation analysis of a rare composite chronic lymphocyte leukemia and lymphoplasmacytic lymphoma by flow cytometry cell sorting., Shi M,Spurgeon S,Press R,Olson S,Fan G,, Annals of hematology, 2015 Nov [PubMed PMID: 26231802]
[12]
[Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia with P53 deletion and TCR-delta rearrangement in a case]., Xu X,Yang W,Zhang X,, Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics, 2015 Oct [PubMed PMID: 26418990]
[13]
MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity., Schmidt J,Federmann B,Schindler N,Steinhilber J,Bonzheim I,Fend F,Quintanilla-Martinez L,, British journal of haematology, 2015 Jun [PubMed PMID: 25819228]
[14]
MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma., Martinez-Lopez A,Curiel-Olmo S,Mollejo M,Cereceda L,Martinez N,Montes-Moreno S,Almaraz C,Revert JB,Piris MA,, The American journal of surgical pathology, 2015 May [PubMed PMID: 25723115]
[15]
Rituximab intolerance in patients with Waldenström macroglobulinaemia., Castillo JJ,Kanan S,Meid K,Manning R,Hunter ZR,Treon SP,, British journal of haematology, 2015 Nov 2 [PubMed PMID: 26523929]
[16]
Waldenstrom macroglobulinemia: prognosis and management., Oza A,Rajkumar SV,, Blood cancer journal, 2015 Mar 27 [PubMed PMID: 25815903]
[17]
BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma., Wiestner A,, Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2014 Dec 5 [PubMed PMID: 25696845]
[19]
Kapoor P,Ansell SM,Braggio E, Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment. Cancer treatment and research. 2016 [PubMed PMID: 27696269]
[20]
Morel P,Duhamel A,Gobbi P,Dimopoulos MA,Dhodapkar MV,McCoy J,Crowley J,Ocio EM,Garcia-Sanz R,Treon SP,Leblond V,Kyle RA,Barlogie B,Merlini G, International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009 Apr 30 [PubMed PMID: 19196866]